OptiBiotix HealthLSE:OPTI Gross Margin % is 51.07% as of Dec. 2025, which is 4% below its 10-year median of 53.39. The stock has 4 warning signs investors should review. Among 732 Biotechnology companies, OptiBiotix Health ranks worse than 58.74% on this metric.
OptiBiotix Health PLC gross margin has been in long-term decline. The average rate of decline per year is -3.9%.
The historical rank and industry rank for OptiBiotix Health's Gross Margin % or its related term are showing as below:
LSE:OPTI'
s Gross Margin % Range Over the Past 10 Years
Min: 38.05 Med: 53.39 Max: 86.81
Current: 52.66
During the past 13 years, the highestGross Margin % of OptiBiotix Health was 86.81%. The lowest was 38.05%. And the median was 53.39%.
LSE:OPTI's Gross Margin % is ranked worse than 58.74% of 732
companies
in the Biotechnology industry
Industry Median: 60.91
vs LSE:OPTI: 52.66
OptiBiotix Health had a gross margin of 51.07% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for OptiBiotix Health was -3.90% per year.
OptiBiotix Health (LSE:OPTI) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
OptiBiotix Health had a gross margin of 51.07% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
OptiBiotix Health Gross Margin % Related Terms
OptiBiotix Health Gross Margin % Historical Data
* Premium members only.
The historical data trend for OptiBiotix Health's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OPTI vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, OptiBiotix Health's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OptiBiotix Health Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OptiBiotix Health's Gross Margin % distribution charts can be found below:
* The bar in red indicates where OptiBiotix Health's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
OptiBiotix Health (LSE:OPTI) has a Gross Margin % of 51.07% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on OptiBiotix Health and its competitors. This is near median its historical median of 53.39. Over the past decade, OptiBiotix Health's Gross Margin % has ranged from 38.05 to 86.81. According to the industry distribution chart, OptiBiotix Health ranks #430 out of 732 companies in the Biotechnology industry, placing it in the top 58.7%.
Is OptiBiotix Health's Gross Margin % too high?
OptiBiotix Health's current Gross Margin % of 51.07% is near median its 10-year median of 53.39. Over the past 10 years, this metric has ranged from a low of 38.05 to a high of 86.81. The Biotechnology industry median Gross Margin % is 60.91. OptiBiotix Health's value of 51.07% is 16.2% below this industry median. Based on the distribution chart, OptiBiotix Health ranks #430 out of 732 companies in the Biotechnology industry, which is below the industry midpoint.
How does OptiBiotix Health's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OptiBiotix Health ranks #430 out of 732 companies for Gross Margin %. This places OptiBiotix Health in the lower half of its industry. The industry median Gross Margin % is 60.91. OptiBiotix Health's value of 51.07% is 16.2% below this benchmark. Historically, OptiBiotix Health's own Gross Margin % has ranged from 38.05 to 86.81 over the past decade. While the company's 10-year median is 53.39 vs. the industry median of 60.91, OptiBiotix Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OptiBiotix Health's current Gross Margin % of 51.07% is 16.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on OptiBiotix Health and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OptiBiotix Health's current Gross Margin % is 51.07%, which is near median its own 10-year median of 53.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptiBiotix Health stock overvalued right now?
Based on GuruFocus' analysis, OptiBiotix Health (LSE:OPTI) is currently considered Possible Value Trap. The stock's GF Value™ is £0.30, compared to a current price of £0.06 — trading 78.5% below its estimated fair value. The current Gross Margin % is 51.07%, which is near median its 10-year median of 53.39 and 16.2% below the Biotechnology industry median of 60.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For OptiBiotix Health (LSE:OPTI), the current Gross Margin % is 51.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OptiBiotix Health PLC principal activity is that of identifying and developing microbial strains, compounds, and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits. It is a life sciences business focused on the development of products which reduce hunger and food cravings, enhance the gut microbiome, and provide a healthy substitute for sugar. Its product portfolio includes First-generation products- SlimBiome, WellBiome; and Second-generation solutions- SweetBiotix, Microbiome Modulators. The group has one class of business. It has presence in United Kingdom, United States, India China, and Rest of world. The company generates majority of revenue from United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OPTI has been successfully added to your 